Analyst Rating Update on Unilife Corporation
Research firm Zacks has rated Unilife Corporation (NASDAQ:UNIS) and has ranked it at 3, indicating that for the short term the shares are a hold. 5 Wall Street analysts have given the company an average rating of 1.4. The shares have received a hold rating based on the suggestion from 1 analysts in latest recommendations. Strong buy was given by 4 Wall Street Analysts.
Unilife Corporation (NASDAQ:UNIS) stock has received a short term price target of $ 8.56 from 4 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $2.44. The higher estimate of target price is $12 , while the lower price target estimate is $6
Company has received recommendation from many analysts. In a research note released to the investors, Griffin Securities downgrades its rating on Unilife Corporation (NASDAQ:UNIS).The analysts at the brokerage house have a current rating of Neutral on the shares. The rating by the firm was issued on July 31, 2015.
Shares of Unilife Corporation (NASDAQ:UNIS) ended Thursday session in red amid volatile trading. The shares closed down 0.11 points or 7.05% at $1.45 with 3,524,429 shares getting traded. Post opening the session at $1.5, the shares hit an intraday low of $1.15 and an intraday high of $1.53 and the price vacillated in this range throughout the day. The company has a market cap of $190 million and the number of outstanding shares have been calculated to be 131,215,000 shares. The 52-week high of Unilife Corporation (NASDAQ:UNIS) is $4.9 and the 52-week low is $1.53.
The company shares have dropped 32.47% in the past 52 Weeks. On January 27, 2015 The shares registered one year high of $4.9 and one year low was seen on August 5, 2015 at $1.53. The 50-day moving average is $2.01 and the 200 day moving average is recorded at $3.18. S&P 500 has rallied 9.96% during the last 52-weeks.
Unilife Corporation (Unilife) is a developer, manufacturer and supplier of injectable drugs delivery systems. The Company manufactures and supplies its devices to pharmaceutical companies in a format where they can be filled and packaged with an injectable therapy prior to its shipment to the end-user. The Companys technology platforms cover six device categories: Prefilled Syringes, Drug Reconstitution Delivery Systems, Auto-Injectors, Wearable Injectors, Ocular Delivery Systems and Delivery Systems.
Do your own DD. Anything I post is for entertainment purpose only and should not assist you in any trading decision based on anything I post.
